Abstract
There is a critical need to develop new strategies to prevent sexual transmission of HIV. Condoms have limited acceptance, and a vaccine may not be available for many years. A vaginal formulation could provide an alternative method if a compound that inhibits sexual transmission of HIV can be identified or synthesized, and if this agent can be formulated for vaginal use. In this report we describe an infection assay for testing compounds that may be useful in a vaginal formulation. This assay system utilizes a cell line (ME-180) derived from the human cervix which, on the basis of morphological features, is an appropriate model of female and male genital and urinary tract epithelia. These cells can be productively infected with HIV upon exposure to HIV-infected T-cell lines. Blocking experiments can be readily carried out in this model because in this p24 ELISA assay system the quantity of virus released by the infected epithelium over a 24-h period is 40 times background.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
